22 citations
,
October 2021 in “Dermatologic Therapy” This study found that approximately one-quarter of post-COVID-19 patients experienced telogen effluvium, with a higher incidence among women, hospitalized patients, and those with hypertension or respiratory symptoms.
November 2022 in “Journal of Investigative Dermatology” This study found that patients with COVID-19 induced telogen effluvium experienced significantly greater cognitive deficits, which were strongly associated with increased symptoms of depression, anxiety, and stress.
November 2022 in “Journal of clinical images and medical case reports” The researchers reported that COVID-induced telogen effluvium can occur after both severe and mild infections, potentially presenting earlier than other causes, and necessitates specific patient management due to its psychological impact.
COVID-19 patients with hair loss experienced more cognitive issues and these issues were linked to higher levels of depression, anxiety, and stress.
March 2024 in “International journal of research in medical sciences” In this study, researchers reported that intradermal injections of Dr. SKS hair booster serum improved hair growth and patient satisfaction in individuals experiencing COVID-19-induced persistent telogen effluvium, with increased benefits observed over six months.
